Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 6Colorectal Neoplasms 3Stomach Neoplasms 2Esophageal Neoplasms 2Biliary Tract Neoplasms 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Hemangiosarcoma 1Gallbladder Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Malignancies 1

Interventions

Bevacizumab 56Cetuximab 50Fluorouracil 45Leucovorin 39Oxaliplatin 38pembrolizumab 31Specimen Handling 27Irinotecan 25Magnetic Resonance Spectroscopy 17Biopsy 17Nivolumab 15HMPL-013 13Folfox protocol 13Capecitabine 13Gemcitabine 12Cisplatin 12trifluridine tipiracil drug combination 11Panitumumab 11Carboplatin 11Pemetrexed 9IFL protocol 9encorafenib 8balstilimab 8Standard of Care 8Paclitaxel 8Early Intervention, Educational 8130-nm albumin-bound paclitaxel 8fludarabine 7atezolizumab 7Educational Status 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Colorectal Neoplasms × zanidatamab × 90 days × Clear all
NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

Phase 1/2 Recruiting
768 enrolled
BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT07405476 2026-04-17

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Emory University

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

Phase 2 Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡